Cargando…
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273868/ https://www.ncbi.nlm.nih.gov/pubmed/34290828 http://dx.doi.org/10.1177/17562872211029784 |
| _version_ | 1783721457766891520 |
|---|---|
| author | Roviello, Giandomenico Buti, Sebastiano Cattrini, Carlo Mennitto, Alessia Messina, Carlo Airoldi, Chiara Vannini, Gianmarco Bersanelli, Melissa |
| author_facet | Roviello, Giandomenico Buti, Sebastiano Cattrini, Carlo Mennitto, Alessia Messina, Carlo Airoldi, Chiara Vannini, Gianmarco Bersanelli, Melissa |
| author_sort | Roviello, Giandomenico |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8273868 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82738682021-07-20 Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? Roviello, Giandomenico Buti, Sebastiano Cattrini, Carlo Mennitto, Alessia Messina, Carlo Airoldi, Chiara Vannini, Gianmarco Bersanelli, Melissa Ther Adv Urol Letter to the Editor SAGE Publications 2021-07-08 /pmc/articles/PMC8273868/ /pubmed/34290828 http://dx.doi.org/10.1177/17562872211029784 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Letter to the Editor Roviello, Giandomenico Buti, Sebastiano Cattrini, Carlo Mennitto, Alessia Messina, Carlo Airoldi, Chiara Vannini, Gianmarco Bersanelli, Melissa Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? |
| title | Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? |
| title_full | Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? |
| title_fullStr | Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? |
| title_full_unstemmed | Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? |
| title_short | Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? |
| title_sort | antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273868/ https://www.ncbi.nlm.nih.gov/pubmed/34290828 http://dx.doi.org/10.1177/17562872211029784 |
| work_keys_str_mv | AT roviellogiandomenico antiangiogenictyrosinekinaseinhibitorsandimmunotherapyasfirstlinetreatmentformetastaticrenalcellcarcinomaisthereanincreasedriskofhypothyroidism AT butisebastiano antiangiogenictyrosinekinaseinhibitorsandimmunotherapyasfirstlinetreatmentformetastaticrenalcellcarcinomaisthereanincreasedriskofhypothyroidism AT cattrinicarlo antiangiogenictyrosinekinaseinhibitorsandimmunotherapyasfirstlinetreatmentformetastaticrenalcellcarcinomaisthereanincreasedriskofhypothyroidism AT mennittoalessia antiangiogenictyrosinekinaseinhibitorsandimmunotherapyasfirstlinetreatmentformetastaticrenalcellcarcinomaisthereanincreasedriskofhypothyroidism AT messinacarlo antiangiogenictyrosinekinaseinhibitorsandimmunotherapyasfirstlinetreatmentformetastaticrenalcellcarcinomaisthereanincreasedriskofhypothyroidism AT airoldichiara antiangiogenictyrosinekinaseinhibitorsandimmunotherapyasfirstlinetreatmentformetastaticrenalcellcarcinomaisthereanincreasedriskofhypothyroidism AT vanninigianmarco antiangiogenictyrosinekinaseinhibitorsandimmunotherapyasfirstlinetreatmentformetastaticrenalcellcarcinomaisthereanincreasedriskofhypothyroidism AT bersanellimelissa antiangiogenictyrosinekinaseinhibitorsandimmunotherapyasfirstlinetreatmentformetastaticrenalcellcarcinomaisthereanincreasedriskofhypothyroidism |